BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21222362)

  • 1. Altered down regulation of the receptor tyrosine kinase met in pancreatic adenocarcinoma cells.
    Hill KS; Lorinczi M; Elferink LA
    J Exp Ther Oncol; 2010; 8(4):297-312. PubMed ID: 21222362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.
    Song X; Akasaka H; Wang H; Abbasgholizadeh R; Shin JH; Zang F; Chen J; Logsdon CD; Maitra A; Bean AJ; Wang H
    J Biol Chem; 2020 Feb; 295(8):2348-2358. PubMed ID: 31959629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation.
    Abella JV; Peschard P; Naujokas MA; Lin T; Saucier C; Urbé S; Park M
    Mol Cell Biol; 2005 Nov; 25(21):9632-45. PubMed ID: 16227611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
    Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
    Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1.
    Matsushita A; Götze T; Korc M
    Cancer Res; 2007 Nov; 67(21):10309-16. PubMed ID: 17974973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic mutations lead to an oncogenic deletion of met in lung cancer.
    Kong-Beltran M; Seshagiri S; Zha J; Zhu W; Bhawe K; Mendoza N; Holcomb T; Pujara K; Stinson J; Fu L; Severin C; Rangell L; Schwall R; Amler L; Wickramasinghe D; Yauch R
    Cancer Res; 2006 Jan; 66(1):283-9. PubMed ID: 16397241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis.
    Sehat B; Andersson S; Girnita L; Larsson O
    Cancer Res; 2008 Jul; 68(14):5669-77. PubMed ID: 18632619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor.
    Timpson P; Lynch DK; Schramek D; Walker F; Daly RJ
    Cancer Res; 2005 Apr; 65(8):3273-80. PubMed ID: 15833860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A MET-PTPRK kinase-phosphatase rheostat controls ZNRF3 and Wnt signaling.
    Kim M; Reinhard C; Niehrs C
    Elife; 2021 Sep; 10():. PubMed ID: 34590584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proto-oncogene c-Cbl is a positive regulator of Met-induced MAP kinase activation: a role for the adaptor protein Crk.
    Garcia-Guzman M; Larsen E; Vuori K
    Oncogene; 2000 Aug; 19(35):4058-65. PubMed ID: 10962563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway.
    Ketterer K; Kong B; Frank D; Giese NA; Bauer A; Hoheisel J; Korc M; Kleeff J; Michalski CW; Friess H
    Cancer Lett; 2009 May; 277(1):72-81. PubMed ID: 19118941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
    Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
    Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Met receptor signaling: a key effector in esophageal adenocarcinoma.
    Anderson MR; Harrison R; Atherfold PA; Campbell MJ; Darnton SJ; Obszynska J; Jankowski JA
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5936-43. PubMed ID: 17062664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines.
    Nakamura Y; Matsubara D; Goto A; Ota S; Sachiko O; Ishikawa S; Aburatani H; Miyazawa K; Fukayama M; Niki T
    Cancer Sci; 2008 Jan; 99(1):14-22. PubMed ID: 17953713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion.
    Murai M; Shen X; Huang L; Carpenter WM; Lin CS; Silverman S; Regezi J; Kramer RH
    Int J Oncol; 2004 Oct; 25(4):831-40. PubMed ID: 15375530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma.
    Liu N; Furukawa T; Kobari M; Tsao MS
    Am J Pathol; 1998 Jul; 153(1):263-9. PubMed ID: 9665487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
    Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
    J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.